Sun.May 28, 2023

article thumbnail

DPSRU hosts workshop on role of councils to facilitate implementation of NEP 2020

Express Pharma

A workshop on Role of Councils to Facilitate Implementation of NEP 2020 was organised at Delhi Pharmaceutical Sciences and Research University, New Delhi on May 20, 2023 under the leadership of Honorable Vice-Chancellor Prof. Ramesh K. Goyal. He summarised in a very precise manner the highlights of NEP 2020 that plays a major role in implementation.

97
article thumbnail

Who’s acquiring who? Orphan designated drugs M&A activity in the pharmaceutical industry decreased by 23% in Q1 2023

Pharmaceutical Technology

Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 20 pharmaceutical deals announced in Q1 2023, worth a total value of $50.2bn. The $43bn acquisition of Seagen by Pfizer was the industry’s largest disclosed deal. GlobalData’s New Drug Approvals and Their Contract Manufacture report provides critical insight into the contract manufacturing organization (CMO) industry by analysing relative performance of major CMOs by number of drug

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Methylene Blue for Autism. Exploring potential benefits and Considerations

Welltopia Pharmacy

Discover the potential benefits of Methylene Blue for Autism management. Explore its mechanisms of action, existing research, dosage considerations, and future prospects in this comprehensive guide.

Dosage 52
article thumbnail

Episode 821: What dose of inhaled tranexamic acid is used for nonmassive hemoptysis?

Pharmacy Joe

In this episode, I’ll discuss the dose of inhaled tranexamic acid used for nonmassive hemoptysis. Episode 821: What dose of inhaled tranexamic acid is used for nonmassive hemoptysis? Subscribe on iTunes , Android , or Stitcher Tranexamic acid (TA) is an antifibrinolytic medication. It forms a reversible complex that displaces plasminogen from fibrin resulting in inhibition of fibrinolysis.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AstraZeneca’s Ultomiris receives Japanese approval for NMOSD

Pharmaceutical Technology

AstraZeneca has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Ultomiris (ravulizumab) to prevent relapses in patients with neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica. The rare and debilitating autoimmune condition NMOSD affects the central nervous system (CNS), including optic nerves and the spine.

article thumbnail

Hypertension Pharmacology Crossword Puzzle

Med Ed 101

We have had a wonderful response to our previous pharmacology crossword on diabetes so I figured I try this again. With the help of a pharmacy student, Kevin Laspa, we have created a free hypertension pharmacology crossword puzzle! (ANSWERS AT THE BOTTOM OF THIS POST) I know some folks out there really like crossword puzzles, so I […] The post Hypertension Pharmacology Crossword Puzzle appeared first on Med Ed 101.

More Trending

article thumbnail

BMS to Present P-III Study (COMMANDS) of Reblozyl (luspatercept-aamt) as 1L Treatment of Anemia in Adults with Lower-Risk MDS at ASCO and EHA 2023

PharmaShots

Shots: The P-III study evaluating Reblozyl vs epoetin alfa for anemia in 363 adult patients with very low, low, or intermediate-risk MDS who require RBC transfusions & are ESA-naïve with median treatment durations of 41.6 & 27wks. 58.5% vs 31.2% achieved the 1EPs of RBC-TI of 12wks. with Hb increase of 1.5g/dL within the first 24wks.; HI-E increase (74.1% vs 51.3%) @8wks. along with more durable responses with a m-DoR of RBC-TI ≥12wks. (126.6 vs 77wks.); RBC-TI (47.6% vs 29.2%) w

40
article thumbnail

Who’s acquiring who? Virtual care M&A activity in the pharmaceutical industry increased by 100% in Q1 2023

Pharmaceutical Technology

Analysis of the key themes driving M&A activity reveals that virtual care accounted for 6 pharmaceutical deals announced in Q1 2023, worth a total value of $426.2m. The $250m merger of Clearday and Viveon Health Acquisition and 98point6 was the industry’s largest disclosed deal. GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on ma

52
article thumbnail

Which pharmaceutical companies have the most drug patents in Lithuania?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.